Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Goldgroup Mining and Gold Resource Corporation Announce Closing of Business Combination and Goldgroup's Anticipated Listing on the NYSE American
Precious Metals & Critical Minerals Virtual Investor Conference Agenda Announced for July 22nd & 23rd
Metalsource Mining Identifies High Priority Drill Targets Across 2.4 Kilometres to Drive the Next Phase of Exploration at Silver Hill
